Safety of Rapid Daratumumab Infusion: A Retrospective, Multicenter, Real-Life Analysis on 134 Patients With Multiple Myeloma

BackgroundThe anti-CD38 monoclonal antibody daratumumab is the backbone of most anti-multiple myeloma (MM) regimens. To mitigate the risk of infusion-related reactions (IRRs), intravenous daratumumab administration requires 7 hours for the first infusion and 3.5-4 hours thereafter, thus making darat...

وصف كامل

التفاصيل البيبلوغرافية

المؤلفون الرئيسيون:	Francesca Bonello, Serena Rocchi, Gregorio Barilà, Michela Sandrone, Marco Talarico, Elena Zamagni, Matilde Scaldaferri, Susanna Vedovato, Cecilia Bertiond, Laura Pavan, Sara Bringhen, Francesco Cattel, Renato Zambello, Michele Cavo, Roberto Mina
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	Frontiers Media S.A. 2022-03-01
سلاسل:	Frontiers in Oncology
الموضوعات:	multiple myeloma daratumumab rapid infusion real life infusion-related reactions
الوصول للمادة أونلاين:	https://www.frontiersin.org/articles/10.3389/fonc.2022.851864/full
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!